The CancerConnect Myeloproliferative Neoplasms MPN Newsletter
Stay Current With PV, ET, MF Treatment Advances & Connect with Others
CancerConnect MPN Newsletter
CancerConnect publishes daily cancer news, original articles and "tips" on the management of ET, PV, and MF. These are available in our monthly MPN newsletter.
Stay Current - Connect With Other MPN Patients
Join The CancerConnect Community: Connect with others and receive regular updates
or
Zenocutuzumab - the first approved systemic therapy for patients with NRG1 fusion–positive NSCLC or pancreatic adenocarcinoma.
Zenocutuzumab targeted therapy approved for treatment of pancreatic ductal adenocarcinoma and non-small cell lung cancer with NRG1 fusions.
Immunotherapy After Chemoradiotherapy Promising in Limited-Stage Small Cell Lung Cancer
Adjuvant therapy with Imfinzi (durvalumab) significantly improved survival outcomes for patients with limited-stage SCLC
Breakthrough in Understanding Tamoxifen's Effectiveness in Breast Cancer: Gut Bacteria Play a Crucial Role
Since tamoxifen is taken orally and travels through the digestive system, variations in patient responses may be connected to the gut microbiome—the trillions of bacteria in our intestines that differ significantly from one person to another.
